Wall Street analysts forecast that Genprex Inc (NASDAQ:GNPX) will announce earnings of ($0.18) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Genprex’s earnings. The firm is expected to announce its next earnings report on Tuesday, February 19th.
On average, analysts expect that Genprex will report full-year earnings of ($0.56) per share for the current fiscal year. For the next financial year, analysts expect that the company will report earnings of ($0.64) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Genprex.
Genprex (NASDAQ:GNPX) last issued its quarterly earnings results on Tuesday, November 20th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).
Shares of GNPX opened at $1.42 on Tuesday. Genprex has a one year low of $1.26 and a one year high of $19.45.
Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.
Read More: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.